Search Within

Heiko Schoder

  1. "Center for Hematologic Malignancies"
Formats
  1. Journal Article (75)
  2. Meeting Abstract (67)
  3. Research Letter (4)
Groups
  1. Center for Hematologic Malignancies (146)
  2. Molecular Imaging and Therapy Service (146)
  3. Radiology, Department of (146)
  4. Department of Medicine (141)
  5. Hematologic Malignancies, Division of (135)
  6. Lymphoma (128)

More Groups

People
  1. Andrew Zelenetz (66)
  2. Alison Moskowitz (59)
  3. David Straus (56)
  4. Ariela Noy (55)
  5. Maria Palomba (53)
  6. Paul Hamlin (51)

More People

Years
  1. 2025 (5)
  2. 2024 (10)
  3. 2023 (17)
  4. 2022 (7)
  5. 2021 (11)
  6. 2020 (10)

More Years

Publications
  1. Blood (49)
  2. Journal of Clinical Oncology (17)
  3. Hematological Oncology (11)
  4. International Journal of Radiation Oncology, Biology, Physics (7)
  5. Blood Advances (6)
  6. Leukemia and Lymphoma (5)

More Publications

Publishers
  1. American Society of Hematology (55)
  2. American Society of Clinical Oncology (17)
  3. Wiley Blackwell (14)
  4. Elsevier Inc. (8)
  5. Nature Publishing Group (6)
  6. Springer (6)

More Publishers

Results (146)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Long-term outcomes of patients with limited-stage ocular adnexal DLBCL treated with combined modality therapy in the rituximab era
    Research Letter

    Qualls, D.; Imber, B. S.; Okwali, M.; Hamlin, P. A.; Kumar, A.; Lahoud, O. B.; Matasar, M. J.; Noy, A.; Owens, C.; Zelenetz, A. D.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • Interim positron emission tomography during frontline chemoimmunotherapy for follicular lymphoma
    Journal Article

    Merryman, R. W.; Michaud, L.; Redd, R.; Mondello, P.; Park, H.; Spilberg, G.; Robertson, M.; Taranto, E.; Ahmed, G.; Chase, M.; more...
    HemaSphere (2023)

    Fulltext@MSK | Save
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Correlative biomarkers for CART19 response in patients with relapsed or refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Batlevi, C. L.; Nos, G.; Kotlov, N.; Sorokina, M.; Okwali, M.; Bagaev, A.; Michaud, L.; Shah, G. L.; Shouval, R.; Tomas, A. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Brentuximab vedotin combined with chemotherapy in newly diagnosed, early-stage, unfavorable-risk Hodgkin lymphoma: Extended follow-up with evaluation of baseline metabolic tumor volume and PET2
    Meeting Abstract

    Stuver, R.; Michaud, L.; Casulo, C.; Advani, R. H.; Budde, E. L.; Barr, P. M.; Batlevi, C. L.; Caron, P. C.; Constine, L. S.; Dandapani, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • The impact of semiautomatic segmentation methods on metabolic tumor volume, intensity, and dissemination radiomics in (18)F-FDG PET scans of patients with classical Hodgkin lymphoma
    Journal Article

    Driessen, J.; Zwezerijnen, G. J. C.; Schòˆder, H.; Drees, E. E. E.; Kersten, M. J.; Moskowitz, A. J.; Moskowitz, C. H.; Eertink, J. J.; de Vet, H. C. W.; Hoekstra, O. S.; more...
    Journal of Nuclear Medicine (2022)

    Fulltext@MSK | Save
  • Patterns of relapse and risk reduction following tumor debulking by bridging radiotherapy prior to chimeric antigen receptor T cell therapy in non-Hodgkin lymphoma
    Meeting Abstract

    Hubbeling, H. G.; Silverman, E. A.; Michaud, L.; Flynn, J.; Devlin, S.; Wijetunga, N. A.; Alarcon Tomas, A.; Shouval, R.; Palomba, M. L.; Batlevi, C. L.; more...
    International Journal of Radiation Oncology, Biology, Physics (2022)

    Fulltext@MSK | Save
  • Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma
    Journal Article

    Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; more...
    Blood Cancer Journal (2022)

    Fulltext@MSK | Save
  • Phase I/Ib study of the efficacy and safety of buparlisib and ibrutinib therapy in MCL, FL, and DLBCL with serial cell-free DNA monitoring
    Journal Article

    Stewart, C. M.; Michaud, L.; Whiting, K.; Nakajima, R.; Nichols, C.; De Frank, S.; Hamlin, P. A. Jr; Matasar, M. J.; Gerecitano, J. F.; Drullinsky, P.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Quantitative change in metabolic tumor volume may assist in distinguishing between pseudoprogressors and responders in patients with relapsed/refractory classical Hodgkin lymphoma treated with PD-1 blockade
    Meeting Abstract

    Wills, B.; Michaud, L.; Schòˆder, H.; Ganesan, N.; Moskowitz, C. H.; Straus, D. J.; Falchi, L.; Matasar, M. J.; Zelenetz, A. D.; Joffe, E.; more...
    Blood (2021)

    Fulltext@MSK | Save